MRNA
$170.73
Moderna
$17.99
11.78%
MRNA
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  ($0.39)
Revenue:  $150.80 Mil
Thursday
Jan 28
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when MRNA reports earnings?
Beat
Meet
Miss

Where is MRNA's stock price going from here?
Up
Flat
Down
Stock chart of MRNA
Analysts
Summary of analysts' recommendations for MRNA
Score
Grade
Pivots
Resistance
$170.21
$162.04
$157.39

$149.22

Support
$144.57
$136.40
$131.75
Tweet
Growth
Description
Moderna Inc. is a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines for patients. The company's product pipeline which is in clinical stage consists of mRNA-1647 for Cytomegalovirus Infectious Disease, mRNA-4157 for Solid tumors, mRNA-2416 for lymphoma and mRNA- 2752 for Relapsed/Refractory solid tumors malignancies. Moderna Inc. is based in Cambridge, United States.